drugset
drugset / Trial / NCT01975779

Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

NCT01975779 ↗

Phase 1 Completed 42 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety and tolerability of single- and multiple doses of Lu AE58054 in healthy young Japanese men in comparison with Caucasian men.

Timeline

Start
2013-07
Primary completion
2013-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Idalopirdine Small molecule 60 mg Oral
Subject Idalopirdine Small molecule 120 mg Oral

Indications

No indication recorded.